All about COVID-19

Private firms ready to test for COVID-19

Companies that offer diagnostic tests say they have the capacity to mass-test for COVID-19 but have mixed responses to India’s policy of restricting testing to government laboratories.

COVID-19 | Interactive map of confirmed coronavirus cases in India

The Mumbai-headquartered Metropolis Labs, a chain of diagnostic labs with a presence across India, said they had already set up a “dedicated and isolated” COVID-19 laboratory and were awaiting the Union Health Ministry’s permission.

State Helpline numbers

The company had already been “approved” by the Mumbai Municipal Commissioner for offering testing services. “We are getting another facility ready on standby and this would be ready in the next seven days. We are importing kits from Altona, Germany for sample testing,” Ameera Shah, Promoter & Managing Director, Metropolis Healthcare Limited, said in a statement.

Watch | COVID-19: Masks and sanitisers are now essential commodities

The tests are real time polymerase chain reaction tests (RT-PCR) that can, within a day — sometimes in hours — confirm the presence of SARS-COV2, the virus responsible for the ongoing pandemic. All of these tests are proprietary products of multinational pharma companies and Indian laboratories must firm up licensing deals, order kits and appropriate chemicals, and train staff to use them.

Other leading laboratories said they were having “discussions” with the Health Ministry regarding allowing private diagnostic companies to test. The Indian Council of Medical Research (ICMR) has currently authorised 65 diagnostic centres across the country and claims to be able to test at least 10,000 a day but, as a policy, has restricted testing to only those showing symptoms — of cough, fever and breathing difficulties — and having a travel history, or a link, to COVID-19-affected countries.

Low mortality

One company official said the relatively low mortality in India and cases compared to other countries and directives to quarantine international travellers were likely guiding India’s approach to testing. “We are interacting with government every day,” said Arvind Lal, Chairman and Managing Director, Lal Pathlabs, “The sense is that the government has enough capacity now and when they needs us we are there. During the swine flu outbreak of 2009, the government eventually involved the private sector and we offered tests at ₹4,500.”

Demand for test kits

Navin Dang, Co-founder and Director, Dr. Dangs Labs, said the industry as a whole was equipped to handle a “million cases in India ” if the need arose, however given the global nature of disease there could be shortages in procuring reagents as well as difficulty in scaling demand to produce test kits. “There’s a concern among people and I’ve personally met some who feel they are sick but are afraid of going to government hospitals. Shouldn’t they have that option?” he argued.

ICMR tests

To concerns that the virus may be circulating among some, undetected, in India — or exhibiting community transmission — the ICMR said it had started to test 150-250 samples from those exhibiting flu symptoms to determine this and would be able to get a sense later this week. “So far we have no evidence. Moreover, restricting testing to government facilities means we can also effectively quarantine and treat patients and monitor their contacts,” R. Gangakhedkar, who leads epidemiology efforts at the ICMR, said at a press briefing on Monday.

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | May 16, 2021 12:51:22 PM |

In This Package
The Hindu Explains | How is India preparing to roll out COVID-19 vaccines?
The Hindu Explains | Why was a COVID-19 vaccine dry run necessary, and how was it organised?
Coronavirus | Why people with prior infection still need COVID-19 vaccination
Explained | What we know about China-made vaccines
How infections among participants are a part of vaccine trials | The Hindu In Focus podcast
The Hindu Explains | What is emergency use authorisation for drugs and vaccines?
Coronavirus | How the new variant quickly accumulated 23 mutations
Coronavirus | New variant does not increase reinfection risk, disease severity, deaths
Coronavirus | N501Y mutation in SARS-CoV-2 virus causes increased infectivity in mice: researchers
The Hindu Explains | Are viruses expected to change form, and will vaccines protect against a mutating SARS-CoV-2?
Coronavirus | Is the first wave coming to an end in India?
Has India passed the COVID-19 peak? | The Hindu Parley podcast
Has India passed its COVID-19 peak, as a new government study claims? | The Hindu In Focus podcast
No evidence to suggest coronavirus cluster 5 variant found in minks increases virus transmissibility, disease severity
SARS-CoV-2 not the last virus to spark a pandemic, says expert
The Hindu Explains | Who are the top contenders in the race for a COVID-19 vaccine?
The vaccine networks India will rely on and the challenges ahead | The Hindu In Focus podcast
Study advances use of indomethacin for treatment of mild cases
How an asymptomatic player turned super-spreader
How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast
WHO warns against pursuing herd immunity to stop coronavirus
Studies document in-flight transmission of coronavirus
Experimental study finds how coronavirus can spread while speaking
Can universal masking be a crude ‘vaccine’?
The Hindu Explains | Is COVID-19 setting off a bradykinin storm in the body?
Coronavirus | Lung damage in COVID-19 dead may shed light on ‘long COVID’: study
The Hindu Explains | What does herd immunity mean for COVID-19?
The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?
Coronavirus | Russian vaccine generated strong immune response, says Lancet study
Watch | Is COVID-19 intensifying in rural India?
The Hindu Explains | Why is Phase-3 of COVID-19 vaccine trial complicated?
The Hindu Explains | What are the long-term effects of COVID-19?
The Hindu Explains | Are there re-infection fears around COVID-19?
Watch | COVID-19 and children
The Hindu Explains | Is SARS-CoV-2 a latent virus which can recur?
Watch | What is an immunity passport?
WHO says COVID-19 by far its worst global health emergency
CDC says revised guidance on coronavirus spread posted in error, removes it
Coronavirus | Plasma therapy may look promising in treating COVID-19, but it is no magic bullet
Coronavirus | Different kinds of SARS-CoV-2 exist in India but none more lethal than the other: Indian Academy of Sciences President
The Hindu Explains | Is airborne transmission of COVID-19 a risk?
Watch | What are serological surveys?
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients?
Video: In conversation with Andrew Pollard, Director of Oxford Vaccine Group
Watch | All you need to know about pulse oximeters
Coronavirus | Why are only a fraction of cases tested?
Coronavirus | Vaccine was rapidly synthesised as novel coronavirus sequence was available, says virologist Gagandeep Kang
A step closer to developing a potent drug against novel coronavirus
Coronavirus | The importance of ‘contact tracing’
Coronavirus | Are diabetics more prone to COVID-19?
You are reading
Private firms ready to test for COVID-19
Coronavirus | How does soap use help in tackling COVID-19?
Fight for the finite: On budgetary allocation for health
Coronavirus | A problematic testing strategy
Fighting COVID-19 together for a shared future
Scientists get ready to test rival COVID-19 pandemic vaccines in animals
Coronavirus | The cost of opacity
Watch | COVID-19: Masks and sanitisers are now essential commodities
A COVID-19 control plan made simple
Watch | Your COVID-19 queries answered
Coronavirus | How is India containing COVID-19?
Battle against COVID-19
Watch | COVID-19: Dos and don'ts from the Health Ministry
A COVID-19 response that is quick off the blocks
Watch | Why is COVID-19 not a pandemic yet?
Watch | Coronavirus: Can masks protect you?
Watch | How is India dealing with coronavirus?
WHO’s unexplained hesitancy
Watch | Bats and the novel coronavirus
Coronavirus | India shares two SARS-CoV-2 genome sequences
COVID-19 | We are in uncharted territory, says WHO
Explained | Why is COVID-19 not a pandemic yet?
New COVID-19 epidemic at ‘decisive point’: WHO chief
COVID-19 vaccine may be ready by 2022: SII
Explainer: How WHO names a new disease
WHO names deadly viral disease from China as 'COVID-19'
Explained | When can people transmit the novel coronavirus?
Analysis | For China’s Xi, the coronavirus challenge comes laden with economic costs and political risks
How bats harbour several viruses yet not get sick
WHO declares coronavirus outbreak a global emergency
Watch | What is Coronavirus?
What is the source of the new SARS-like disease reported in China?
Data | The wide, rapid spread of the novel coronavirus
Alarming spread: on novel coronavirus outbreak
Gaps in our knowledge of coronavirus origin need fulfilment: Study
A new virus emerges in China
Next Story